Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

• Revenue in USD (TTM)47.40m
• Net income in USD-58.12m
• Incorporated1969
• Employees105.00

• Location
  Vaxart Inc170 Harbor Way, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
• Phone+1 (650) 550-3500
• Fax+1 (650) 871-8580
• Websitehttps://vaxart.com/